Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to $229000.0.

  • Rockwell Medical's Capital Expenditures rose 1989.53% to $229000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $851000.0, marking a year-over-year increase of 2913.51%. This contributed to the annual value of $1.0 million for FY2024, which is 25598.59% up from last year.
  • Rockwell Medical's Capital Expenditures amounted to $229000.0 in Q3 2025, which was up 1989.53% from $164000.0 recorded in Q2 2025.
  • In the past 5 years, Rockwell Medical's Capital Expenditures registered a high of $395000.0 during Q4 2024, and its lowest value of -$80000.0 during Q3 2022.
  • For the 5-year period, Rockwell Medical's Capital Expenditures averaged around $134421.1, with its median value being $127000.0 (2021).
  • As far as peak fluctuations go, Rockwell Medical's Capital Expenditures tumbled by 16299.21% in 2022, and later soared by 109375.0% in 2024.
  • Quarter analysis of 5 years shows Rockwell Medical's Capital Expenditures stood at $114000.0 in 2021, then skyrocketed by 146.49% to $281000.0 in 2022, then tumbled by 84.7% to $43000.0 in 2023, then surged by 818.6% to $395000.0 in 2024, then plummeted by 42.03% to $229000.0 in 2025.
  • Its Capital Expenditures was $229000.0 in Q3 2025, compared to $164000.0 in Q2 2025 and $63000.0 in Q1 2025.